Change language dansk English suomi svenska

Generate Estimates Confirm Cancel Hide empty rows Show hidden rows DummyText

CiVi Biopharma A/S Estimate generation in progress, please wait... 0%

Quicksearch from your own companies XBRLDenmark Analyst: XBRLDenmark

Loading... Loading... Loading... Loading...   Loading...

1000.0 Bankruptcy Risk  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Bankruptcy risk for industry   1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 1.2% 1.2%   Bankruptcy risk   2.7% 2.1% 6.0% 6.1% 11.9% 17.0% 11.2% 10.9%   Credit score (0-100)   62 69 39 37 19 9 22 22   Credit rating   BBB A BBB BBB BB BB BB BB   Credit limit (kDKK)   0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0   How are these values calculated?   View the automatically generated explanation of bankruptcy risk 1000.0 Income statement (kDKK)  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   0 0 0 0 0 0 0 0   Gross profit   6,039 7,237 4,485 4,036 3,530 3,502 0.0 0.0   EBITDA   912 843 515 453 430 402 0.0 0.0   EBIT   912 843 515 453 430 402 0.0 0.0   Pre-tax profit (PTP)   908.9 833.8 503.1 441.8 419.4 -1,798.4 0.0 0.0   Net earnings   706.7 648.7 392.0 344.0 326.3 -1,887.3 0.0 0.0   Pre-tax profit without non-rec. items   909 834 503 442 419 -1,798 0.0 0.0     See the entire income statement 1000.0 Balance sheet (kDKK)  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Tangible assets total   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Shareholders equity total   1,664 2,313 2,705 3,049 3,375 1,488 988 988   Interest-bearing liabilities   4,646 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   7,037 4,599 4,114 4,332 3,948 2,285 988 988   Net Debt   3,908 -1,376 -2,472 -2,282 -249 -329 -988 -988     See the entire balance sheet 1000.0 Volume  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   0 0 0 0 0 0 0 0   Net sales growth   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Gross profit   6,039 7,237 4,485 4,036 3,530 3,502 0.0 0.0   Gross profit growth   42.8% 19.8% -38.0% -10.0% -12.5% -0.8% -100.0% 0.0%   Employees   1 1 1 1 1 1 0 0   Employee growth %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% -100.0% 0.0%   Employee expenses   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   7,037 4,599 4,114 4,332 3,948 2,285 988 988   Balance sheet change%   243.0% -34.7% -10.5% 5.3% -8.9% -42.1% -56.8% 0.0%   Added value   912.0 842.7 515.1 452.8 430.2 401.8 0.0 0.0   Added value %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Investments   0 0 0 0 0 0 0 0   Net sales trend   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   EBIT trend   2.0 3.0 4.0 5.0 5.0 5.0 0.0 0.0   1000.0 Profitability  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A EBITDA %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT to gross profit (%)   15.1% 11.6% 11.5% 11.2% 12.2% 11.5% 0.0% 0.0%   Net Earnings %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Profit before depreciation and extraordinary items %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Pre tax profit less extraordinaries %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   ROA %   20.1% 14.5% 11.8% 10.7% 10.4% 83.4% 0.0% 0.0%   ROI %   23.9% 19.6% 20.5% 15.7% 13.4% -73.8% 0.0% 0.0%   ROE %   53.9% 32.6% 15.6% 12.0% 10.2% -77.6% 0.0% 0.0%   1000.0 Solidity  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Equity ratio %   23.7% 50.3% 65.7% 70.4% 85.5% 65.1% 100.0% 100.0%   Relative indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Relative net indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net int. bear. debt to EBITDA, %   428.5% -163.3% -479.8% -504.1% -57.9% -82.0% 0.0% 0.0%   Gearing %   279.2% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net interest   0 0 0 0 0 0 0 0   Financing costs %   0.1% 0.4% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   1000.0 Liquidity  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Quick Ratio   1.3 2.0 2.9 3.4 6.9 2.9 0.0 0.0   Current Ratio   1.3 2.0 2.9 3.4 6.9 2.9 0.0 0.0   Cash and cash equivalent   738.6 1,375.8 2,471.5 2,282.3 248.9 329.5 0.0 0.0   1000.0 Capital use efficiency  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Trade debtors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Trade creditors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Current assets / Net sales %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net working capital   1,640.2 2,294.7 2,705.0 3,049.0 3,375.4 1,488.0 0.0 0.0   Net working capital %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   1000.0 Employee efficiency  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales / employee   0 0 0 0 0 0 0 0   Added value / employee   912 843 515 453 430 402 0 0   Employee expenses / employee   0 0 0 0 0 0 0 0   EBITDA / employee   912 843 515 453 430 402 0 0   EBIT / employee   912 843 515 453 430 402 0 0   Net earnings / employee   707 649 392 344 326 -1,887 0 0